What can your test results reveal about your AML treatment options? Dr. David Sallman explains how genetic mutations and other test results can impact treatment decisions, including the potential use of targeted therapies. He also discusses why having comprehensive testing before starting treatment can make a critical difference in finding the best approach to care.
Dr. David Sallman is an Associate Member in the Department of Malignant Hematology at Moffitt Cancer Center where he specializes in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Learn more about Dr. Sallman.
Related Resources
Transcript
Katherine Banwell:
Dr. Sallman, what do test results tell us about a patient’s AML?
Dr. David Sallman:
Yeah, so the test results really tell us everything. I mean, there are still basic clinical factors. Is a patient truly unfit? Let’s say, they’re over the age of 80, or maybe they have major medical problems and they’re younger, because this can kind of dictate, “Are we going to try to cure our patient, or is cure really not a possibility?” But let’s say for a majority of patients that may be under the age of 80 and let’s say fit for transplants.
Our treatment strategies could vary dramatically based on what mutations. And even in the truly unfit group, there are some molecular subsets – particularly patients with IDH mutations – where I already, from a standard of care perspective, give a different regimen. So, really for everybody, you need the data.
And that’s why I strongly, strongly recommend that AML therapy should never begin until we actually have all of these data. There are only rare exceptions. If somebody is really actively dying from leukemia infiltration from that perspective and I really have to emergently treat them, but that is probably 5 percent of patients at best.
And so, there’s been this 911 reflex. You have AML; I need therapy tomorrow. And that’s, unfortunately, the very wrong reflex to have because a lot of patients may be missing the optimal treatment approach.